On November 4, 2026 Immuto Scientific, an AI-enabled therapeutics company discovering disease-specific, cell surface structural targets and developing advanced antibody-based medicines against them, reported two upcoming presentations showing how its structural surfaceomics approach uncovered first-in-class targets in colorectal cancer (CRC) and acute myeloid leukemia (AML) to support the development of precision antibody-based medicines. The research will be presented at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) (ENA) Symposium on Molecular Targets and Cancer Therapeutics and the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentations illustrate two stages of Immuto’s strategy. At ENA 2026, Immuto will present research from its collaboration with the University of Wisconsin-Madison applying structural surfaceomics in patient-derived colorectal cancer models to identify new target opportunities. At the ASH (Free ASH Whitepaper) 2026 Annual Meeting, Immuto will present preclinical data on IMTO-4842.1, a mutation-agnostic ADC directed against an AML-specific surface protein conformer.
"These presentations show why disease-specific protein structure matters for drug discovery," said Faraz A. Choudhury, Ph.D., co-founder and CEO of Immuto Scientific. "By measuring structural changes on the surface of diseased cells, we can uncover target opportunities that conventional approaches can’t capture. The colorectal cancer study demonstrates the breadth of that discovery capability, while IMTO-4842.1 shows how we are translating a distinct target into a precision antibody-based therapeutic program for acute myeloid leukemia."
ENA 2026 Presentation
Title: Discovery of Novel Surface Protein Conformer (SPC) Targets in RAS Colorectal Cancer
Abstract: 219
Topic: Molecular Targeted Agents
Presenter: Neal C. Goodwin, Ph.D., Chief Scientific Officer, Immuto Scientific
Date and time: Thursday, November 19, 9:00 a.m.-5:30 p.m. CET
Poster board: PB-114
Location: Exhibition Hall, ENA 2026, Barcelona, Spain
ASH 2026 Presentation
Title: IMTO-4842.1, a Mutation-Agnostic ADC Targeting an AML-Specific Surface Protein Conformer with a Favorable Preclinical Therapeutic Index
Publication number: 3250
Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II
Presenter: Neal C. Goodwin, Ph.D., Chief Scientific Officer, Immuto Scientific
Date and time: Sunday, December 13, 6:00-8:00 p.m. CST
Location: Ernest N. Morial Convention Center, Hall F, New Orleans, Louisiana, and online
(Press release, Immuto Scientific, NOV 4, 2026, View Source [SID1234674230])